Sun, Jul 13, 2014, 12:07 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • zzzdq zzzdq Feb 19, 2002 7:46 PM Flag

    AVI Execs. to speak at Roth conference

    Is this the news we are waiting for?

    http://biz.yahoo.com/bw/020219/190761_1.html

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • newsiscomingblablahblablah newsiscomingblablahblablah Feb 20, 2002 11:15 AM Flag

      I saw the last PR release as some damage control after yesterdays performance.

    • wherestherestofthismoose wherestherestofthismoose Feb 20, 2002 11:10 AM Flag

      Dr. Burger has been commenting on things for a long time. I'm now waiting for results of these comments. I get tired of talk only. Do we know if this new media relations firm handled this past release? The way it looks to me, is that the old PR firm still does work for Avi. If you look at their releases it still mentions the old firm. There is a difference between "Media Relations" (new firm) and "Public Relations" (old firm). I think the wire announcements are put out by the old firm.? I think? which would actually make sense based on the timing of the last release. Doesn't it?

    • Tuesday February 19, 6:57 pm Eastern Time
      Press Release
      SOURCE: AVI BioPharma Inc.
      AVI BioPharma Executives to Speak at Roth Capital Partners and BIO CEO Investor Conferences
      PORTLAND, Ore.--(BW HealthWire)--Feb. 19, 2002--AVI BioPharma Inc. (Nasdaq:AVII - news; Nasdaq:AVIIW - news; Nasdaq:AVIIZ - news) today announced that company executives will speak at two prominent investor and biotechnology conferences this week.

      AVI's President and Chief Operating Officer, Alan Timmins, will present today at the Roth Capital Partners Growth Stock Conference in Laguna Niguel, Calif., and Denis Burger, Ph.D., the company's chief executive officer, will present at the BIO CEO and Investor Conference on Thursday, Feb. 21, in New York City.

      Burger and Timmins will discuss the company's progress with its two core technology platforms: NEUGENE� antisense and cancer immunotherapy. In addition, both executives will demonstrate the broad applicability and versatility of these two platforms -- as well as market and partnership opportunities.

      ``AVI is the only company that is in clinical development with novel third-generation antisense technology that can address a variety of life-threatening diseases,'' Burger said. ``Our approach bypasses the lengthy process most drug companies must undergo to develop a drug to block the disease-causing gene. This puts us in a great position to develop new therapies and add significant value to therapies currently marketed.''

      Speaking times for Timmins and Burger are as follows:


      14th Annual Roth Capital Partner Growth Stock Conference
      The Ritz-Carlton, Laguna Niguel, Calif., Feb. 18-20, 2002
      Speaker: Alan Timmins, President and COO
      Date: Feb. 19, 2002
      Time: 5 p.m. PT
      BIO CEO and Investor Conference

      Walldorf-Astoria, New York City, Feb. 20-22, 2002

      Speaker: Denis Burger, CEO

      Date: Feb. 21, 2002

      Time: 5:20 p.m. ET

      AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: NEUGENE antisense drugs and cancer immunotherapy. Its lead cancer agent, AVICINE� a therapeutic cancer vaccine, has completed three Phase II trials in colorectal and pancreatic cancer and is in a Phase III pivotal trial in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene c-myc. It is currently in Phase II trials for restenosis and in Phase I/II trials for cancer and polycystic kidney disease. More information about AVI is available on the Company's Web site at http://www.avibio.com/.

      • 2 Replies to zzzdq
      • what does this part refer to:

        ``AVI is the only company that is in clinical development with novel third-generation antisense technology that can address a variety of life-threatening diseases,'' Burger said.

        ``Our approach bypasses the lengthy process most drug companies must undergo to develop a drug to block the disease-causing gene.

        This puts us in a great position to develop new therapies and add significant value to therapies currently marketed.''

      • wherestherestofthismoose wherestherestofthismoose Feb 19, 2002 9:02 PM Flag

        This news means nothing. Roth Capital as far as I know is an unimportant firm (at least in Avi's future). The conference in NY is a more influencial one. But there's a lot of companies there, and we're going to hear the same things we always hear. Some new news would be good!

 
SRPT
21.98-0.56(-2.48%)Jul 11 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
MGIC Investment Corp.
NYSEFri, Jul 11, 2014 4:01 PM EDT